Published in Mar Drugs on January 04, 2010
Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents (2002) 2.97
Marine natural products as anticancer drugs. Mol Cancer Ther (2005) 2.93
Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol (2009) 2.05
Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem (1991) 1.97
Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res (2004) 1.81
Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells. Mol Cancer Ther (2003) 1.61
A common pharmacophore for cytotoxic natural products that stabilize microtubules. Proc Natl Acad Sci U S A (1999) 1.49
A simple but remarkably effective device for forming the C8-C14 polycyclic ring system of halichondrin B. J Am Chem Soc (2004) 1.21
Synergistic suppression of microtubule dynamics by discodermolide and paclitaxel in non-small cell lung carcinoma cells. Cancer Res (2004) 1.13
The clinical development of new mitotic inhibitors that stabilize the microtubule. Anticancer Drugs (2004) 1.12
Marine peptides and related compounds in clinical trial. Anticancer Agents Med Chem (2006) 1.09
(+)-Discodermolide: Total Synthesis, Construction of Novel Analogues, and Biological Evaluation. Tetrahedron (2007) 1.07
The halichondrins and E7389. Chem Rev (2009) 1.07
Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies. J Med Chem (2007) 1.02
Stereochemistry of kahalalide F. J Nat Prod (2003) 1.02
Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer. Clin Cancer Res (2005) 1.01
Synthetic efforts toward the C22-C36 subunit of halichondrin B utilizing local and imposed symmetry. Org Lett (2005) 0.99
Adding pharmacogenomics to the development of new marine-derived anticancer agents. J Transl Med (2006) 0.90
Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors. Clin Cancer Res (2008) 0.86
The structure activity relationship of discodermolide analogues. Mini Rev Med Chem (2008) 0.85
Iron chelators in medicinal applications - chemical equilibrium considerations in pharmaceutical activity. Curr Med Chem (2009) 0.82
Naturally occurring esterification reactions with bryostatin. Nat Prod Res (2008) 0.81
The epothilones, eleutherobins, and related types of molecules. Curr Pharm Des (2001) 0.80
Computational studies of Fe(III) binding to bryostatins, bryostatin analogs, siderophores and marine natural products: arguments for ferric complexes in medicinal applications. Nat Prod Res (2008) 0.77
Iron chelators in medicinal applications - chemical equilibrium considerations in pharmaceutical activity. Curr Med Chem (2009) 0.82
Impact of environmental conditions on the marine natural product bryostatin 1. Nat Prod Res (2006) 0.80
The Trauma Time-Out: Evaluating the Effectiveness of Protocol-Based Information Dissemination in the Traumatically Injured Patient. J Trauma Nurs (2017) 0.75